New treatment targeting tau protein for frontotemporal dementia
Development of a brain penetrating single-chain antibody selectively targeting three repeat tau protein as a new treatment for frontotemporal dementia
This study is working on a new treatment that uses a special antibody to target a specific type of tau protein in the brain, aiming to help people with frontotemporal dementia feel better and improve their symptoms.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | 3rt Innovations NIH-funded |
| Lab location | 1 site (Manhattan Beach, United States) |
| Project ID | NIH-10383261 on NIH RePORTER |
What this research studies
This research focuses on developing a specialized antibody that can penetrate the brain and selectively target a specific form of tau protein associated with frontotemporal dementia (FTD). The approach aims to address the underlying tau pathology that contributes to the symptoms of FTD, which include severe behavioral changes and cognitive decline. By targeting the three-repeat tau isoform, the research seeks to create a more effective treatment option for patients suffering from this condition. The methodology involves advanced antibody engineering techniques to ensure that the treatment can effectively reach and act on the affected areas of the brain.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with frontotemporal dementia, particularly those exhibiting symptoms related to the three-repeat tau protein.
Not a fit: Patients with other forms of dementia or those not expressing the three-repeat tau isoform may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves the quality of life for patients with frontotemporal dementia.
How similar studies have performed: While there has been significant interest in targeting tau proteins, this specific approach using a brain-penetrating antibody is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Manhattan Beach, United States
- 3rt Innovations — Manhattan Beach, United States (Active)
Researchers
- Principal investigator: Saito, Erin — 3rt Innovations
- Study coordinator: Saito, Erin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.